Skip to main content

Advertisement

SpringerLink
Log in

Tumor Necrosis Factor-α in Heart Failure: an Updated Review

  • Myocardial Disease (A Abbate, Section Editor)
  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Purpose of the Review

Proinflammatory cytokines are consistently elevated in congestive heart failure. In the current review, we provide an overview on the current understanding of how tumor necrosis factor-α (TNFα), a key proinflammatory cytokine, potentiates heart failure by overwhelming the anti-inflammatory responses disrupting the homeostasis.

Recent Findings

Studies have shown co-relationship between severity of heart failure and levels of the proinflammatory cytokine TNFα and one of its secondary mediators interleukin-6 (IL-6), suggesting their potential as biomarkers. Recent efforts have focused on understanding the mechanisms of how proinflammatory cytokines contribute towards cardiac dysfunction and failure. In addition, how unchecked proinflammatory cytokines and their cross-talk with sympathetic system overrides the anti-inflammatory response underlying failure.

Summary

The review offers insights on how TNFα and IL-6 contribute to cardiac dysfunction and failure. Furthermore, this provides a forum to begin the discussion on the cross-talk between sympathetic drive and proinflammatory cytokines and its determinant role in deleterious outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: •• Of major Importance

  1. Chung MW, Tsoutsman T, Semsarian C. Hypertrophic cardiomyopathy: from gene defect to clinical disease. Cell Res. 2003;13:9–20.

    CAS  PubMed  Google Scholar 

  2. Yndestad A, Damas JK, Oie E, Ueland T, Gullestad L, Aukrust P. Role of inflammation in the progression of heart failure. Curr Cardiol Rep. 2007;9:236–41.

    PubMed  Google Scholar 

  3. Francis GS, Tang WH. Pathophysiology of congestive heart failure. Rev Cardiovasc Med. 2003;4(Suppl 2):S14–20.

    PubMed  Google Scholar 

  4. Lefkowitz RJ, Willerson JT. Prospects for cardiovascular research. JAMA. 2001;285:581–7.

    CAS  PubMed  Google Scholar 

  5. Braunwald E. Shattuck lecture--cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med. 1997;337:1360–9.

    CAS  PubMed  Google Scholar 

  6. Valen G. Innate immunity and remodelling. Heart Fail Rev. 2011;16:71–8.

    CAS  PubMed  Google Scholar 

  7. •• Mann DL. Innate immunity and the failing heart: the cytokine hypothesis revisited. Circ Res. 2015;116:1254–68 This article provides discussion on the mechanisms that underlie the initial response to cardiac injury and how an unchecked inflammatory response could overwhelm the anti-inflammatory resolution processes.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Gullestad L, Ueland T, Vinge LE, Finsen A, Yndestad A, Aukrust P. Inflammatory cytokines in heart failure: mediators and markers. Cardiology. 2012;122:23–35.

    CAS  PubMed  Google Scholar 

  9. •• Bartekova M, Radosinska J, Jelemensky M and Dhalla NS. Role of cytokines and inflammation in heart function during health and disease. Heart Fail Rev. 2018. The review details the signlaing mechanism involved in mediating the effects of cytokines in cells with a focus on NF-κB, a key central transcirption factor that is activated in response to proinflammatory cytokines.

  10. Ionita MG, Arslan F, de Kleijn DP, Pasterkamp G. Endogenous inflammatory molecules engage Toll-like receptors in cardiovascular disease. J Innate Immun. 2010;2:307–15.

    CAS  PubMed  Google Scholar 

  11. Mann DL. The emerging role of innate immunity in the heart and vascular system: for whom the cell tolls. Circ Res. 2011;108:1133–45.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Libby P, Simon DI. Inflammation and thrombosis: the clot thickens. Circulation. 2001;103:1718–20.

    CAS  PubMed  Google Scholar 

  13. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation. 2004;109:II2–10.

    PubMed  Google Scholar 

  14. Mann DL. Stress-activated cytokines and the heart: from adaptation to maladaptation. Annu Rev Physiol. 2003;65:81–101.

    CAS  PubMed  Google Scholar 

  15. Ramadori G, Van Damme J, Rieder H, Meyer zum Buschenfelde KH. Interleukin 6, the third mediator of acute-phase reaction, modulates hepatic protein synthesis in human and mouse. Comparison with interleukin 1 beta and tumor necrosis factor-alpha. Eur J Immunol. 1988;18:1259–64.

    CAS  PubMed  Google Scholar 

  16. •• Mohan ML, Vasudevan NT, Naga Prasad SV. Proinflammatory cytokines mediate GPCR dysfunction. J Cardiovasc Pharmacol. 2017;70:61–73 This manusript provides in-depth discussion on the cross-talk between the proinflammatory cytokines and G-protein coupled receptors describing how these cytokines inhibit receptor function.

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Mommersteeg PM, Kupper N, Schoormans D, Emons W, Pedersen SS. Health-related quality of life is related to cytokine levels at 12 months in patients with chronic heart failure. Brain Behav Immun. 2010;24:615–22.

    CAS  PubMed  Google Scholar 

  18. Hartupee J, Mann DL. Positioning of inflammatory biomarkers in the heart failure landscape. J Cardiovasc Transl Res. 2013;6:485–92.

    PubMed  Google Scholar 

  19. Ueland T, Gullestad L, Nymo SH, Yndestad A, Aukrust P, Askevold ET. Inflammatory cytokines as biomarkers in heart failure. Clin Chim Acta. 2015;443:71–7.

    CAS  PubMed  Google Scholar 

  20. Divakaran VG, Evans S, Topkara VK, Diwan A, Burchfield J, Gao F, et al. Tumor necrosis factor receptor-associated factor 2 signaling provokes adverse cardiac remodeling in the adult Mammalian heart. Circulation Heart Failure. 2013;6:535–43.

    CAS  PubMed  PubMed Central  Google Scholar 

  21. Garlie JB, Hamid T, Gu Y, Ismahil MA, Chandrasekar B, Prabhu SD. Tumor necrosis factor receptor 2 signaling limits beta-adrenergic receptor-mediated cardiac hypertrophy in vivo. Basic Research in Cardiology. 2011;106:1193–205.

    CAS  PubMed  Google Scholar 

  22. Vasudevan NT, Mohan ML, Gupta MK, Martelli EE, Hussain AK, Qin Y, et al. Gbetagamma-independent recruitment of G-protein coupled receptor kinase 2 drives tumor necrosis factor alpha-induced cardiac beta-adrenergic receptor dysfunction. Circulation. 2013;128:377–87.

    CAS  PubMed  Google Scholar 

  23. Prabhu SD. Cytokine-induced modulation of cardiac function. Circulation research. 2004;95:1140–53.

    CAS  PubMed  Google Scholar 

  24. Rockman HA, Koch WJ, Lefkowitz RJ. Seven-transmembrane-spanning receptors and heart function. Nature. 2002;415:206–12.

    CAS  PubMed  Google Scholar 

  25. Rathinam VA, Jiang Z, Waggoner SN, Sharma S, Cole LE, Waggoner L, et al. The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. Nat Immunol. 2010;11:395–402.

    CAS  PubMed  PubMed Central  Google Scholar 

  26. Mezzaroma E, Toldo S, Farkas D, Seropian IM, Van Tassell BW, Salloum FN, et al. The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse. Proc Natl Acad Sci U S A. 2011;108:19725–30.

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Matzinger P. Friendly and dangerous signals: is the tissue in control? Nat Immunol. 2007;8:11–3.

    CAS  PubMed  Google Scholar 

  28. Mann DL, Topkara VK, Evans S, Barger PM. Innate immunity in the adult mammalian heart: for whom the cell tolls. Trans Am Clin Climatol Assoc. 2010;121:34–50 discussion 50–1.

    PubMed  PubMed Central  Google Scholar 

  29. Matzinger P. The danger model: a renewed sense of self. Science. 2002;296:301–5.

    CAS  PubMed  Google Scholar 

  30. Whelan RS, Kaplinskiy V, Kitsis RN. Cell death in the pathogenesis of heart disease: mechanisms and significance. Annu Rev Physiol. 2010;72:19–44.

    CAS  PubMed  Google Scholar 

  31. Gottlieb RA, Carreira RS. Autophagy in health and disease. 5. Mitophagy as a way of life. Am J Physiol Cell Physiol. 2010;299:C203–10.

    CAS  PubMed  PubMed Central  Google Scholar 

  32. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004;4:499–511.

    CAS  PubMed  Google Scholar 

  33. Yan ZQ, Hansson GK. Innate immunity, macrophage activation, and atherosclerosis. Immunol Rev. 2007;219:187–203.

    CAS  PubMed  Google Scholar 

  34. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell. 2010;140:805–20.

    CAS  PubMed  Google Scholar 

  35. Palm NW, Medzhitov R. Pattern recognition receptors and control of adaptive immunity. Immunol Rev. 2009;227:221–33.

    CAS  PubMed  Google Scholar 

  36. Erickson B, Sperber K, Frishman WH. Toll-like receptors: new therapeutic targets for the treatment of atherosclerosis, acute coronary syndromes, and myocardial failure. Cardiol Rev. 2008;16:273–9.

    PubMed  Google Scholar 

  37. Frantz S, Ertl G, Bauersachs J. Mechanisms of disease: Toll-like receptors in cardiovascular disease. Nat Clin Pract Cardiovasc Med. 2007;4:444–54.

    CAS  PubMed  Google Scholar 

  38. Geddes K, Magalhaes JG, Girardin SE. Unleashing the therapeutic potential of NOD-like receptors. Nat Rev Drug Discov. 2009;8:465–79.

    CAS  PubMed  Google Scholar 

  39. Kawaguchi M, Takahashi M, Hata T, Kashima Y, Usui F, Morimoto H, et al. Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury. Circulation. 2011;123:594–604.

    CAS  PubMed  Google Scholar 

  40. Nishimura M, Naito S. Tissue-specific mRNA expression profiles of human toll-like receptors and related genes. Biol Pharm Bull. 2005;28:886–92.

    CAS  PubMed  Google Scholar 

  41. Lech M, Susanti HE, Rommele C, Grobmayr R, Gunthner R, Anders HJ. Quantitative expression of C-type lectin receptors in humans and mice. Int J Mol Sci. 2012;13:10113–31.

    CAS  PubMed  PubMed Central  Google Scholar 

  42. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature. 2003;425:516–21.

    CAS  PubMed  Google Scholar 

  43. Medzhitov R. Origin and physiological roles of inflammation. Nature. 2008;454:428–35.

    CAS  PubMed  Google Scholar 

  44. Fildes JE, Shaw SM, Yonan N, Williams SG. The immune system and chronic heart failure: is the heart in control? J Am Coll Cardiol. 2009;53:1013–20.

    CAS  PubMed  Google Scholar 

  45. Birks EJ, Latif N, Owen V, Bowles C, Felkin LE, Mullen AJ, et al. Quantitative myocardial cytokine expression and activation of the apoptotic pathway in patients who require left ventricular assist devices. Circulation. 2001;104:I233–40.

    CAS  PubMed  Google Scholar 

  46. Tang H, Zhong Y, Zhu Y, Zhao F, Cui X, Wang Z. Low responder T cell susceptibility to the suppressive function of regulatory T cells in patients with dilated cardiomyopathy. Heart. 2010;96:765–71.

    CAS  PubMed  Google Scholar 

  47. Tang TT, Ding YJ, Liao YH, Yu X, Xiao H, Xie JJ, et al. Defective circulating CD4CD25+Foxp3+CD127(low) regulatory T-cells in patients with chronic heart failure. Cell Physiol Biochem. 2010;25:451–8.

    CAS  PubMed  Google Scholar 

  48. Kvakan H, Kleinewietfeld M, Qadri F, Park JK, Fischer R, Schwarz I, et al. Regulatory T cells ameliorate angiotensin II-induced cardiac damage. Circulation. 2009;119:2904–12.

    CAS  PubMed  Google Scholar 

  49. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT, Anti TNFTACHFI. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003;107:3133–40.

    CAS  PubMed  Google Scholar 

  50. Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 2004;109:1594–602.

    CAS  PubMed  Google Scholar 

  51. Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res. 2002;91:988–98.

    CAS  PubMed  Google Scholar 

  52. Lawrence T, Fong C. The resolution of inflammation: anti-inflammatory roles for NF-kappaB. Int J Biochem Cell Biol. 2010;42:519–23.

    CAS  PubMed  Google Scholar 

  53. Hall G, Hasday JD, Rogers TB. Regulating the regulator: NF-kappaB signaling in heart. J Mol Cell Cardiol. 2006;41:580–91.

    CAS  PubMed  Google Scholar 

  54. Jones WK, Brown M, Wilhide M, He S, Ren X. NF-kappaB in cardiovascular disease: diverse and specific effects of a “general” transcription factor? Cardiovasc Toxicol. 2005;5:183–202.

    CAS  PubMed  Google Scholar 

  55. Li C, Browder W, Kao RL. Early activation of transcription factor NF-kappaB during ischemia in perfused rat heart. Am J Physiol. 1999;276:H543–52.

    CAS  PubMed  Google Scholar 

  56. Li C, Kao RL, Ha T, Kelley J, Browder IW, Williams DL. Early activation of IKKbeta during in vivo myocardial ischemia. Am J Physiol Heart Circ Physiol. 2001;280:H1264–71.

    CAS  PubMed  Google Scholar 

  57. Sun SC. The noncanonical NF-kappaB pathway. Immunol Rev. 2012;246:125–40.

    PubMed  PubMed Central  Google Scholar 

  58. Gordon JW, Shaw JA, Kirshenbaum LA. Multiple facets of NF-kappaB in the heart: to be or not to NF-kappaB. Circ Res. 2011;108:1122–32.

    CAS  PubMed  Google Scholar 

  59. Seta Y, Shan K, Bozkurt B, Oral H, Mann DL. Basic mechanisms in heart failure: the cytokine hypothesis. J Card Fail. 1996;2:243–9.

    CAS  PubMed  Google Scholar 

  60. Prabhu SD, Frangogiannis NG. The biological basis for cardiac repair after myocardial infarction: from inflammation to fibrosis. Circ Res. 2016;119:91–112.

    CAS  PubMed  PubMed Central  Google Scholar 

  61. Massion PB, Feron O, Dessy C, Balligand JL. Nitric oxide and cardiac function: ten years after, and continuing. Circ Res. 2003;93:388–98.

    CAS  PubMed  Google Scholar 

  62. Prabhu SD. Nitric oxide protects against pathological ventricular remodeling: reconsideration of the role of NO in the failing heart. Circ Res. 2004;94:1155–7.

    CAS  PubMed  Google Scholar 

  63. Kojda G, Kottenberg K. Regulation of basal myocardial function by NO. Cardiovasc Res. 1999;41:514–23.

    CAS  PubMed  Google Scholar 

  64. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science. 1992;257:387–9.

    CAS  PubMed  Google Scholar 

  65. McGowan FX Jr, Takeuchi K, del Nido PJ, Davis PJ, Lancaster JR Jr, Hattler BG. Myocardial effects of interleukin-2. Transplant Proc. 1994;26:209–10.

    CAS  PubMed  Google Scholar 

  66. Kinugawa K, Takahashi T, Kohmoto O, Yao A, Aoyagi T, Momomura S, et al. Nitric oxide-mediated effects of interleukin-6 on [Ca2+]i and cell contraction in cultured chick ventricular myocytes. Circ Res. 1994;75:285–95.

    CAS  PubMed  Google Scholar 

  67. Sugishita K, Kinugawa K, Shimizu T, Harada K, Matsui H, Takahashi T, et al. Cellular basis for the acute inhibitory effects of IL-6 and TNF- alpha on excitation-contraction coupling. J Mol Cell Cardiol. 1999;31:1457–67.

    CAS  PubMed  Google Scholar 

  68. Goldhaber JI, Kim KH, Natterson PD, Lawrence T, Yang P, Weiss JN. Effects of TNF-alpha on [Ca2+]i and contractility in isolated adult rabbit ventricular myocytes. Am J Physiol. 1996;271:H1449–55.

    CAS  PubMed  Google Scholar 

  69. Alloatti G, Penna C, De Martino A, Montrucchio G, Camussi G. Role of nitric oxide and platelet-activating factor in cardiac alterations induced by tumor necrosis factor-alpha in the guinea-pig papillary muscle. Cardiovasc Res. 1999;41:611–9.

    CAS  PubMed  Google Scholar 

  70. Hofmann U, Domeier E, Frantz S, Laser M, Weckler B, Kuhlencordt P, et al. Increased myocardial oxygen consumption by TNF-alpha is mediated by a sphingosine signaling pathway. Am J Physiol Heart Circ Physiol. 2003;284:H2100–5.

    CAS  PubMed  Google Scholar 

  71. Panas D, Khadour FH, Szabo C, Schulz R. Proinflammatory cytokines depress cardiac efficiency by a nitric oxide-dependent mechanism. Am J Physiol. 1998;275:H1016–23.

    CAS  PubMed  Google Scholar 

  72. Cain BS, Meldrum DR, Dinarello CA, Meng X, Joo KS, Banerjee A, et al. Tumor necrosis factor-alpha and interleukin-1beta synergistically depress human myocardial function. Crit Care Med. 1999;27:1309–18.

    CAS  PubMed  Google Scholar 

  73. Kumar A, Brar R, Wang P, Dee L, Skorupa G, Khadour F, et al. Role of nitric oxide and cGMP in human septic serum-induced depression of cardiac myocyte contractility. Am J Physiol. 1999;276:R265–76.

    CAS  PubMed  Google Scholar 

  74. Bartel S, Stein B, Eschenhagen T, Mende U, Neumann J, Schmitz W, et al. Protein phosphorylation in isolated trabeculae from nonfailing and failing human hearts. Mol Cell Biochem. 1996;157:171–9.

    CAS  PubMed  Google Scholar 

  75. Grandel U, Fink L, Blum A, Heep M, Buerke M, Kraemer HJ, et al. Endotoxin-induced myocardial tumor necrosis factor-alpha synthesis depresses contractility of isolated rat hearts: evidence for a role of sphingosine and cyclooxygenase-2-derived thromboxane production. Circulation. 2000;102:2758–64.

    CAS  PubMed  Google Scholar 

  76. Yokoyama T, Vaca L, Rossen RD, Durante W, Hazarika P, Mann DL. Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. J Clin Invest. 1993;92:2303–12.

    CAS  PubMed  PubMed Central  Google Scholar 

  77. Edmunds NJ, Lal H, Woodward B. Effects of tumour necrosis factor-alpha on left ventricular function in the rat isolated perfused heart: possible mechanisms for a decline in cardiac function. Br J Pharmacol. 1999;126:189–96.

    CAS  PubMed  PubMed Central  Google Scholar 

  78. Oral H, Dorn GW 2nd, Mann DL. Sphingosine mediates the immediate negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian cardiac myocyte. J Biol Chem. 1997;272:4836–42.

    CAS  PubMed  Google Scholar 

  79. Kolesnick R. The therapeutic potential of modulating the ceramide/sphingomyelin pathway. J Clin Invest. 2002;110:3–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  80. Liu B, Andrieu-Abadie N, Levade T, Zhang P, Obeid LM, Hannun YA. Glutathione regulation of neutral sphingomyelinase in tumor necrosis factor-alpha-induced cell death. J Biol Chem. 1998;273:11313–20.

    CAS  PubMed  Google Scholar 

  81. Jayadev S, Linardic CM, Hannun YA. Identification of arachidonic acid as a mediator of sphingomyelin hydrolysis in response to tumor necrosis factor alpha. J Biol Chem. 1994;269:5757–63.

    CAS  PubMed  Google Scholar 

  82. Friedrichs GS, Swillo RE, Jow B, Bridal T, Numann R, Warner LM, et al. Sphingosine modulates myocyte electrophysiology, induces negative inotropy, and decreases survival after myocardial ischemia. J Cardiovasc Pharmacol. 2002;39:18–28.

    CAS  PubMed  Google Scholar 

  83. Dettbarn CA, Betto R, Salviati G, Palade P, Jenkins GM, Sabbadini RA. Modulation of cardiac sarcoplasmic reticulum ryanodine receptor by sphingosine. J Mol Cell Cardiol. 1994;26:229–42.

    CAS  PubMed  Google Scholar 

  84. Schreur KD, Liu S. Involvement of ceramide in inhibitory effect of IL-1 beta on L-type Ca2+ current in adult rat ventricular myocytes. Am J Phys. 1997;272:H2591–8.

    CAS  Google Scholar 

  85. Torre-Amione G, Kapadia S, Lee J, Bies RD, Lebovitz R, Mann DL. Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation. 1995;92:1487–93.

    CAS  PubMed  Google Scholar 

  86. Stamm C, Cowan DB, Friehs I, Noria S, del Nido PJ, McGowan FX Jr. Rapid endotoxin-induced alterations in myocardial calcium handling: obligatory role of cardiac TNF-alpha. Anesthesiology. 2001;95:1396–405.

    CAS  PubMed  Google Scholar 

  87. Edmunds NJ, Woodward B. Effects of tumour necrosis factor-alpha on the coronary circulation of the rat isolated perfused heart: a potential role for thromboxane A2 and sphingosine. Br J Pharmacol. 1998;124:493–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  88. Stamm C, Friehs I, Cowan DB, Moran AM, Cao-Danh H, Duebener LF, et al. Inhibition of tumor necrosis factor-alpha improves postischemic recovery of hypertrophied hearts. Circulation. 2001;104:I350–5.

    CAS  PubMed  Google Scholar 

  89. Cailleret M, Amadou A, Andrieu-Abadie N, Nawrocki A, Adamy C, Ait-Mamar B, et al. N-acetylcysteine prevents the deleterious effect of tumor necrosis factor-(alpha) on calcium transients and contraction in adult rat cardiomyocytes. Circulation. 2004;109:406–11.

    CAS  PubMed  Google Scholar 

  90. Robinson BS, Hii CS, Poulos A, Ferrante A. Activation of neutral sphingomyelinase in human neutrophils by polyunsaturated fatty acids. Immunology. 1997;91:274–80.

    CAS  PubMed  PubMed Central  Google Scholar 

  91. Mazurais D, Robert P, Gout B, Berrebi-Bertrand I, Laville MP, Calmels T. Cell type-specific localization of human cardiac S1P receptors. J Histochem Cytochem. 2002;50:661–70.

    CAS  PubMed  Google Scholar 

  92. Morales-Ruiz M, Lee MJ, Zollner S, Gratton JP, Scotland R, Shiojima I, et al. Sphingosine 1-phosphate activates Akt, nitric oxide production, and chemotaxis through a Gi protein/phosphoinositide 3-kinase pathway in endothelial cells. J Biol Chem. 2001;276:19672–7.

    CAS  PubMed  Google Scholar 

  93. Amadou A, Nawrocki A, Best-Belpomme M, Pavoine C, Pecker F. Arachidonic acid mediates dual effect of TNF-alpha on Ca2+ transients and contraction of adult rat cardiomyocytes. Am J Physiol Cell Physiol. 2002;282:C1339–47.

    CAS  PubMed  Google Scholar 

  94. Liu SJ, McHowat J. Stimulation of different phospholipase A2 isoforms by TNF-alpha and IL-1beta in adult rat ventricular myocytes. Am J Physiol. 1998;275:H1462–72.

    CAS  PubMed  Google Scholar 

  95. Damron DS, Summers BA. Arachidonic acid enhances contraction and intracellular Ca2+ transients in individual rat ventricular myocytes. Am J Physiol. 1997;272:H350–9.

    CAS  PubMed  Google Scholar 

  96. de Bracco MM, Fink SB, Finiasz MR, Borda ES, Sterin-Borda L. Positive inotropic effect of interleukin-2. Role of phospholipases and protein kinase C. Int J Immunopharmacol. 1991;13:509–15.

    PubMed  Google Scholar 

  97. Fink SB, Finiasz M, Sterin-Borda L, Borda E, de Bracco MM. Stimulation of heart contractility by supernatants from lectin-activated lymphocytes. Role of IL-2. Int J Immunopharmacol. 1989;11:367–70.

    CAS  PubMed  Google Scholar 

  98. Kang JX, Leaf A. Effects of long-chain polyunsaturated fatty acids on the contraction of neonatal rat cardiac myocytes. Proc Natl Acad Sci U S A. 1994;91:9886–90.

    CAS  PubMed  PubMed Central  Google Scholar 

  99. Pavoine C, Magne S, Sauvadet A, Pecker F. Evidence for a beta2-adrenergic/arachidonic acid pathway in ventricular cardiomyocytes. Regulation by the beta1-adrenergic/camp pathway. J Biol Chem. 1999;274:628–37.

    CAS  PubMed  Google Scholar 

  100. Kumar A, Kosuri R, Kandula P, Dimou C, Allen J, Parrillo JE. Effects of epinephrine and amrinone on contractility and cyclic adenosine monophosphate generation of tumor necrosis factor alpha-exposed cardiac myocytes. Crit Care Med. 1999;27:286–92.

    CAS  PubMed  Google Scholar 

  101. Liu SJ, Zhou W, Kennedy RH. Suppression of beta-adrenergic responsiveness of L-type Ca2+ current by IL-1beta in rat ventricular myocytes. Am J Physiol. 1999;276:H141–8.

    CAS  PubMed  Google Scholar 

  102. De Paepe B, Creus KK, De Bleecker JL. The tumor necrosis factor superfamily of cytokines in the inflammatory myopathies: potential targets for therapy. Clin Dev Immunol. 2012;2012:369432.

    PubMed  Google Scholar 

  103. Yndestad A, Damas JK, Geir Eiken H, Holm T, Haug T, Simonsen S, et al. Increased gene expression of tumor necrosis factor superfamily ligands in peripheral blood mononuclear cells during chronic heart failure. Cardiovasc Res. 2002;54:175–82.

    CAS  PubMed  Google Scholar 

  104. Loncar G, Bozic B, Cvorovic V, Radojicic Z, Dimkovic S, Markovic N, et al. Relationship between RANKL and neuroendocrine activation in elderly males with heart failure. Endocrine. 2010;37:148–56.

    CAS  PubMed  Google Scholar 

  105. Burchfield JS, Dong JW, Sakata Y, Gao F, Tzeng HP, Topkara VK, et al. The cytoprotective effects of tumor necrosis factor are conveyed through tumor necrosis factor receptor-associated factor 2 in the heart. Circ Heart Fail. 2010;3:157–64.

    CAS  PubMed  Google Scholar 

  106. Cabal-Hierro L, Lazo PS. Signal transduction by tumor necrosis factor receptors. Cell Signal. 2012;24:1297–305.

    CAS  PubMed  Google Scholar 

  107. Al-Lamki RS, Wang J, Vandenabeele P, Bradley JA, Thiru S, Luo D, et al. TNFR1- and TNFR2-mediated signaling pathways in human kidney are cell type-specific and differentially contribute to renal injury. FASEB J. 2005;19:1637–45.

    CAS  PubMed  Google Scholar 

  108. Faustman DL, Davis M. TNF Receptor 2 and Disease: Autoimmunity and Regenerative Medicine. Front Immunol. 2013;4:478.

    PubMed  PubMed Central  Google Scholar 

  109. Torre-Amione G, Kapadia S, Lee J, Durand JB, Bies RD, Young JB, et al. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation. 1996;93:704–11.

    CAS  PubMed  Google Scholar 

  110. Dibbs ZI, Diwan A, Nemoto S, DeFreitas G, Abdellatif M, Carabello BA, et al. Targeted overexpression of transmembrane tumor necrosis factor provokes a concentric cardiac hypertrophic phenotype. Circulation. 2003;108:1002–8.

    CAS  PubMed  Google Scholar 

  111. Diwan A, Dibbs Z, Nemoto S, DeFreitas G, Carabello BA, Sivasubramanian N, et al. Targeted overexpression of noncleavable and secreted forms of tumor necrosis factor provokes disparate cardiac phenotypes. Circulation. 2004;109:262–8.

    CAS  PubMed  Google Scholar 

  112. Li X, Moody MR, Engel D, Walker S, Clubb FJ Jr, Sivasubramanian N, et al. Cardiac-specific overexpression of tumor necrosis factor-alpha causes oxidative stress and contractile dysfunction in mouse diaphragm. Circulation. 2000;102:1690–6.

    CAS  PubMed  Google Scholar 

  113. Kubota T, McTiernan CF, Frye CS, Slawson SE, Lemster BH, Koretsky AP, et al. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res. 1997;81:627–35.

    CAS  PubMed  Google Scholar 

  114. Gulick T, Chung MK, Pieper SJ, Lange LG, Schreiner GF. Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte beta-adrenergic responsiveness. Proc Natl Acad Sci U S A. 1989;86:6753–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  115. Chung MK, Gulick TS, Rotondo RE, Schreiner GF, Lange LG. Mechanism of cytokine inhibition of beta-adrenergic agonist stimulation of cyclic AMP in rat cardiac myocytes. Impairment of signal transduction. Circ Res. 1990;67:753–63.

    CAS  PubMed  Google Scholar 

  116. Muller-Werdan U, Schumann H, Fuchs R, Reithmann C, Loppnow H, Koch S, et al. Tumor necrosis factor alpha (TNF alpha) is cardiodepressant in pathophysiologically relevant concentrations without inducing inducible nitric oxide-(NO)-synthase (iNOS) or triggering serious cytotoxicity. J Mol Cell Cardiol. 1997;29:2915–23.

    CAS  PubMed  Google Scholar 

  117. Tan KS, Nackley AG, Satterfield K, Maixner W, Diatchenko L, Flood PM. Beta2 adrenergic receptor activation stimulates pro-inflammatory cytokine production in macrophages via PKA- and NF-kappaB-independent mechanisms. Cell Signal. 2007;19:251–60.

    CAS  PubMed  Google Scholar 

  118. Verhoeckx KC, Doornbos RP, Witkamp RF, van der Greef J, Rodenburg RJ. Beta-adrenergic receptor agonists induce the release of granulocyte chemotactic protein-2, oncostatin M, and vascular endothelial growth factor from macrophages. Int Immunopharmacol. 2006;6:1–7.

    CAS  PubMed  Google Scholar 

  119. Kim MH, Gorouhi F, Ramirez S, Granick JL, Byrne BA, Soulika AM, et al. Catecholamine stress alters neutrophil trafficking and impairs wound healing by beta2-adrenergic receptor-mediated upregulation of IL-6. J Investig Dermatol. 2014;134:809–17.

    CAS  PubMed  Google Scholar 

  120. Roth Flach RJ, Matevossian A, Akie TE, Negrin KA, Paul MT, Czech MP. beta3-Adrenergic receptor stimulation induces E-selectin-mediated adipose tissue inflammation. J Biol Chem. 2013;288:2882–92.

    CAS  PubMed  Google Scholar 

  121. Prabhu SD, Chandrasekar B, Murray DR, Freeman GL. beta-adrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling. Circulation. 2000;101:2103–9.

    CAS  PubMed  Google Scholar 

  122. Chandrasekar B, Marelli-Berg FM, Tone M, Bysani S, Prabhu SD, Murray DR. Beta-adrenergic stimulation induces interleukin-18 expression via beta2-AR, PI3K, Akt, IKK, and NF-kappaB. Biochem Biophys Res Commun. 2004;319:304–11.

    CAS  PubMed  Google Scholar 

  123. Chandrasekar B, Vemula K, Surabhi RM, Li-Weber M, Owen-Schaub LB, Jensen LE, et al. Activation of intrinsic and extrinsic proapoptotic signaling pathways in interleukin-18-mediated human cardiac endothelial cell death. J Biol Chem. 2004;279:20221–33.

    CAS  PubMed  Google Scholar 

  124. Grisanti LA, Repas AA, Talarico JA, Gold JI, Carter RL, Koch WJ, et al. Temporal and gefitinib-sensitive regulation of cardiac cytokine expression via chronic beta-adrenergic receptor stimulation. Am J Physiol Heart Circ Physiol. 2015;308:H316–30.

    CAS  PubMed  Google Scholar 

  125. Pera T, Penn RB. Bronchoprotection and bronchorelaxation in asthma: New targets, and new ways to target the old ones. Pharmacol Ther. 2016;164:82–96.

    CAS  PubMed  PubMed Central  Google Scholar 

  126. Koch WJ, Lefkowitz RJ, Rockman HA. Functional consequences of altering myocardial adrenergic receptor signaling. Annu Rev Physiol. 2000;62:237–60.

    CAS  PubMed  Google Scholar 

  127. Koch WJ, Rockman HA, Samama P, Hamilton RA, Bond RA, Milano CA, et al. Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor. Science. 1995;268:1350–3.

    CAS  PubMed  Google Scholar 

  128. Lefkowitz RJ. G protein-coupled receptors. III. New roles for receptor kinases and beta-arrestins in receptor signaling and desensitization. J Biol Chem. 1998;273:18677–80.

    CAS  PubMed  Google Scholar 

  129. Garcia-Guerra L, Nieto-Vazquez I, Vila-Bedmar R, Jurado-Pueyo M, Zalba G, Diez J, et al. G protein-coupled receptor kinase 2 plays a relevant role in insulin resistance and obesity. Diabetes. 2010;59:2407–17.

    CAS  PubMed  PubMed Central  Google Scholar 

  130. Lefkowitz RJ, Rockman HA, Koch WJ. Catecholamines, cardiac beta-adrenergic receptors, and heart failure. Circulation. 2000;101:1634–7.

    CAS  PubMed  Google Scholar 

  131. White DC, Hata JA, Shah AS, Glower DD, Lefkowitz RJ, Koch WJ. Preservation of myocardial beta-adrenergic receptor signaling delays the development of heart failure after myocardial infarction. Proc Natl Acad Sci U S A. 2000;97:5428–33.

    CAS  PubMed  PubMed Central  Google Scholar 

  132. Hamid T, Gu Y, Ortines RV, Bhattacharya C, Wang G, Xuan YT, et al. Divergent tumor necrosis factor receptor-related remodeling responses in heart failure: role of nuclear factor-kappaB and inflammatory activation. Circulation. 2009;119:1386–97.

    CAS  PubMed  PubMed Central  Google Scholar 

  133. Kalliolias GD, Ivashkiv LB. TNF biology, pathogenic mechanisms and emerging therapeutic strategies. Nat Rev Rheumatol. 2016;12:49–62.

    CAS  PubMed  Google Scholar 

  134. Hotamisligil GS. The role of TNFalpha and TNF receptors in obesity and insulin resistance. J Intern Med. 1999;245:621–5.

    CAS  PubMed  Google Scholar 

  135. Felten SY, Madden KS, Bellinger DL, Kruszewska B, Moynihan JA, Felten DL. The role of the sympathetic nervous system in the modulation of immune responses. Adv Pharmacol. 1998;42:583–7.

    CAS  PubMed  Google Scholar 

  136. Felten DL, Felten SY, Bellinger DL, Lorton D. Noradrenergic and peptidergic innervation of secondary lymphoid organs: role in experimental rheumatoid arthritis. Eur J Clin Invest. 1992;22(Suppl 1):37–41.

    CAS  PubMed  Google Scholar 

  137. Felten SY, Felten DL, Bellinger DL, Olschowka JA. Noradrenergic and peptidergic innervation of lymphoid organs. Chem Immunol. 1992;52:25–48.

    CAS  PubMed  Google Scholar 

  138. Friedman EM, Irwin MR. Modulation of immune cell function by the autonomic nervous system. Pharmacol Ther. 1997;74:27–38.

    CAS  PubMed  Google Scholar 

  139. Bellinger DL, Millar BA, Perez S, Carter J, Wood C, ThyagaRajan S, et al. Sympathetic modulation of immunity: relevance to disease. Cell Immunol. 2008;252:27–56.

    CAS  PubMed  PubMed Central  Google Scholar 

  140. Eskandari F, Sternberg EM. Neural-immune interactions in health and disease. Ann N Y Acad Sci. 2002;966:20–7.

    CAS  PubMed  Google Scholar 

  141. Hatfield SM, Petersen BH, DiMicco JA. Beta-adrenergic agonists blocked the expression of IL-2 receptors on mitogen-stimulated lymphocytes and IL-2-dependent T cell lines. J Immunol. 1988;141:1418–20.

    CAS  PubMed  Google Scholar 

  142. Oberbeck R. Catecholamines: physiological immunomodulators during health and illness. Curr Med Chem. 2006;13:1979–89.

    CAS  PubMed  Google Scholar 

  143. Stevens-Felten SY, Bellinger DL. Noradrenergic and peptidergic innervation of lymphoid organs. Chem Immunol. 1997;69:99–131.

    CAS  PubMed  Google Scholar 

  144. Heijnen CJ, Kavelaars A. The importance of being receptive. J Neuroimmunol. 1999;100:197–202.

    CAS  PubMed  Google Scholar 

  145. Kin NW, Sanders VM. It takes nerve to tell T and B cells what to do. J Leukoc Biol. 2006;79:1093–104.

    CAS  PubMed  Google Scholar 

  146. Sitkauskiene B, Sakalauskas R. The role of beta(2)-adrenergic receptors in inflammation and allergy. Curr Drug Targets Inflamm Allergy. 2005;4:157–62.

    CAS  PubMed  Google Scholar 

  147. Vasudevan NT, Mohan ML, Goswami SK, Naga Prasad SV. Regulation of beta-adrenergic receptor function: an emphasis on receptor resensitization. Cell Cycle. 2011;10:3684–91.

    CAS  PubMed  PubMed Central  Google Scholar 

  148. Madden KS, Felten SY, Felten DL, Bellinger DL. Sympathetic nervous system--immune system interactions in young and old Fischer 344 rats. Ann N Y Acad Sci. 1995;771:523–34.

    CAS  PubMed  Google Scholar 

  149. Madden KS, Felten DL. Experimental basis for neural-immune interactions. Physiol Rev. 1995;75:77–106.

    CAS  PubMed  Google Scholar 

  150. Madden KS, Sanders VM, Felten DL. Catecholamine influences and sympathetic neural modulation of immune responsiveness. Annu Rev Pharmacol Toxicol. 1995;35:417–48.

    CAS  PubMed  Google Scholar 

  151. Nance DM, Sanders VM. Autonomic innervation and regulation of the immune system (1987–2007). Brain Behav Immun. 2007;21:736–45.

    CAS  PubMed  PubMed Central  Google Scholar 

  152. Link AA, Kino T, Worth JA, JL MG, Crane ML, Chrousos GP, et al. Ligand-activation of the adenosine A2a receptors inhibits IL-12 production by human monocytes. J Immunol. 2000;164:436–42.

    CAS  PubMed  Google Scholar 

  153. Benarroch EE. Autonomic-mediated immunomodulation and potential clinical relevance. Neurology. 2009;73:236–42.

    PubMed  Google Scholar 

  154. Elenkov I. Neuroendocrine effects on immune system. In: L. J. De Groot, G. Chrousos, K. Dungan, K. R. Feingold, A. Grossman, J. M. Hershman, C. Koch, M. Korbonits, R. McLachlan, M. New, J. Purnell, R. Rebar, F. Singer and A. Vinik, eds. Endotext South Dartmouth (MA); 2000.

  155. Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES. The sympathetic nerve--an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev. 2000;52:595–638.

    CAS  PubMed  Google Scholar 

  156. Imrich R, Tibenska E, Koska J, Ksinantova L, Kvetnansky R, Bergendiova-Sedlackova K, et al. Repeated stress-induced stimulation of catecholamine response is not followed by altered immune cell redistribution. Ann N Y Acad Sci. 2004;1018:266–72.

    CAS  PubMed  Google Scholar 

  157. Zhang X, Hartung JE, Bortsov AV, Kim S, O'Buckley SC, Kozlowski J, et al. Sustained stimulation of beta2- and beta3-adrenergic receptors leads to persistent functional pain and neuroinflammation. Brain Behav Immun. 2018.

  158. Bierhaus A, Humpert PM, Nawroth PP. Linking stress to inflammation. Anesthesiol Clin. 2006;24:325–40.

    CAS  PubMed  Google Scholar 

  159. Sanders VM, Straub RH. Norepinephrine, the beta-adrenergic receptor, and immunity. Brain Behav Immun. 2002;16:290–332.

    CAS  PubMed  Google Scholar 

  160. Kiecolt-Glaser JK, Glaser R. Depression and immune function: central pathways to morbidity and mortality. J Psychosom Res. 2002;53:873–6.

    PubMed  Google Scholar 

  161. Kiecolt-Glaser JK, McGuire L, Robles TF, Glaser R. Psychoneuroimmunology: psychological influences on immune function and health. J Consult Clin Psychol. 2002;70:537–47.

    PubMed  Google Scholar 

  162. Loudon RP, Perussia B, Benovic JL. Differentially regulated expression of the G-protein-coupled receptor kinases, betaARK and GRK6, during myelomonocytic cell development in vitro. Blood. 1996;88:4547–57.

    CAS  PubMed  Google Scholar 

  163. Lombardi MS, Kavelaars A, Schedlowski M, Bijlsma JW, Okihara KL, Van de Pol M, et al. Decreased expression and activity of G-protein-coupled receptor kinases in peripheral blood mononuclear cells of patients with rheumatoid arthritis. FASEB J. 1999;13:715–25.

    CAS  PubMed  Google Scholar 

  164. Vroon A, Kavelaars A, Limmroth V, Lombardi MS, Goebel MU, Van Dam AM, et al. G protein-coupled receptor kinase 2 in multiple sclerosis and experimental autoimmune encephalomyelitis. J Immunol. 2005;174:4400–6.

    CAS  PubMed  Google Scholar 

  165. Hata JA, Williams ML, Schroder JN, Lima B, Keys JR, Blaxall BC, et al. Lymphocyte levels of GRK2 (betaARK1) mirror changes in the LVAD-supported failing human heart: lower GRK2 associated with improved beta-adrenergic signaling after mechanical unloading. J Card Fail. 2006;12:360–8.

    CAS  PubMed  Google Scholar 

  166. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature. 1997;385:729–33.

    CAS  PubMed  Google Scholar 

  167. Hsu H, Shu HB, Pan MG, Goeddel DV. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell. 1996;84:299–308.

    CAS  PubMed  Google Scholar 

  168. Brenner D, Blaser H, Mak TW. Regulation of tumour necrosis factor signalling: live or let die. Nat Rev Immunol. 2015;15:362–74.

    CAS  PubMed  Google Scholar 

  169. Bianchi K, Meier P. A tangled web of ubiquitin chains: breaking news in TNF-R1 signaling. Mol Cell. 2009;36:736–42.

    CAS  PubMed  Google Scholar 

  170. Al-Lamki RS, Brookes AP, Wang J, Reid MJ, Parameshwar J, Goddard MJ, et al. TNF receptors differentially signal and are differentially expressed and regulated in the human heart. Am J Transpl. 2009;9:2679–96.

    CAS  Google Scholar 

  171. Grell M, Douni E, Wajant H, Lohden M, Clauss M, Maxeiner B, et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell. 1995;83:793–802.

    CAS  PubMed  Google Scholar 

  172. Sun M, Dawood F, Wen WH, Chen M, Dixon I, Kirshenbaum LA, et al. Excessive tumor necrosis factor activation after infarction contributes to susceptibility of myocardial rupture and left ventricular dysfunction. Circulation. 2004;110:3221–8.

    CAS  PubMed  Google Scholar 

Download references

Funding

The work in part is supported by NIH ROO HL132882 and Cleveland Clinic Startup funds (S.M.S) and by NIH RO1 HL089473 and HL128382 (S.V.NP).

Author information

Authors and Affiliations

  1. NB50, Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, 44195, USA

    Sarah M. Schumacher & Sathyamangla V. Naga Prasad

Authors
  1. Sarah M. Schumacher
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sathyamangla V. Naga Prasad
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sathyamangla V. Naga Prasad.

Ethics declarations

Conflict of Interest

Sarah M. Schumacher and Sathyamangla V. Naga Prasad declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Myocardial Disease

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schumacher, S.M., Naga Prasad, S.V. Tumor Necrosis Factor-α in Heart Failure: an Updated Review. Curr Cardiol Rep 20, 117 (2018). https://doi.org/10.1007/s11886-018-1067-7

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11886-018-1067-7

Keywords

Search

Navigation